| Title | The effects of a commercially available weight loss program among obese patients with type 2 diabetes: a randomized study. | | Author(s) | Foster GD, Borradaile KE, Vander Veur SS, Leh Shantz K, Dilks RJ, Goldbacher EM, Oliver TL, Lagrotte CA, Homko C, Satz W | | Institution | Center for Obesity Research and Education, Temple University, Philadelphia, PA 19140, USA. gfoster@temple.edu | | Source | Postgrad Med 2009 Sep; 121(5):113-8. | | MeSH | Adult
Aged
Anthropometry
Behavior Therapy
Cholesterol
Diabetes Mellitus, Type 2
Female
Hemoglobin A, Glycosylated
Humans
Male
Middle Aged
Motor Activity
Obesity
Psychotherapy, Group
Quality of Life
Treatment Outcome
Triglycerides
Weight Loss
| | Abstract | The purpose of this study was to assess the effects of a commercially available weight loss program on weight and glycemic control among obese patients with type 2 diabetes. Participants included 69 patients (49 females, 20 males) with type 2 diabetes who had a mean +/- SD age of 52.2 +/- 9.5 years, a body mass index of 39.0 +/- 6.2 kg/m(2), and hemoglobin A1c (HbA1c) of 7.5 +/- 1.6%. Over half (52.2%) of the participants were African American. Participants were randomly assigned to: 1) a portion-controlled diet (NutriSystem D) (PCD) or 2) a diabetes support and education (DSE) program. After the initial 3 months, the PCD group continued on the PCD for the remaining 3 months, and the DSE group crossed over to PCD for the remaining 3 months. The primary comparison for this study was at 3 months. At 3 months, the PCD group lost significantly more weight (7.1 +/- 4%) than the DSE group (0.4 +/- 2.3%) (P < 0.0001). From 3 to 6 months the change in weight for both groups was statistically significant. After 3 months, the PCD group had greater reductions in HbA1c than the DSE group (-0.88 +/- 1.1 vs 0.03 +/- 1.09; P < 0.001). From 3 to 6 months the PCD group had no further change in HbA1c, while the DSE group showed a significant reduction. These data suggest that obese patients with type 2 diabetes will experience significant improvements in weight, glycemic control, and cardiovascular disease risk factors after the use of a commercially available weight management program. | | Language | eng | | Pub Type(s) | Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
| | PubMed ID | 19820280 |
|
